HeyJaredMillie Nelson
- Indexed articles, last 90 days
- 55
- Latest publication
- Oct 1, 2026
- Outlet visibility, for SCM
- Top 10M sites
- Earliest in this view
- Jul 10, 2026
Latest articles
Novo and Hengrui strike $2.6bn obesity drug deal (opens the original)
Read excerpt
Novo Nordisk has secured exclusive global rights to Hengrui Pharma’s once-weekly oral therapy that could reshape metabolic disease treatment. The asset in question is Hengrui’s HRS-1596, a Phase I-ready dual receptor agonist targeting both the glucagon-like peptide-1 (GLP-1) receptor and the gastric inhibitory polypeptide receptor. The Danish pharmaceutical giant will pay Hengrui an upfront sum of $300 million, with the remaining $2.3 billion contingent on achieving specific development, regulat
Sofinnova secures $93m to build tomorrow's medtech pioneers (opens the original)
Read excerpt
European venture capital firm Sofinnova Partners has closed an oversubscribed fund dedicated to creating medical device companies from scratch. The Paris-based life sciences VC company’s new fund Sofinnova MD Start IV represents a substantial increase from its predecessor, Sofinnova MD Start III, which closed at €63 million ($71 million). This growth trajectory underscores the expanding appetite for early-stage medtech innovation. The fund will launch between six and eight new medtech ventures o
AstraZeneca pours $2bn into Summit to advance cancer treatment (opens the original)
Read excerpt
The investment centers on ivonescimab, Summit Therapeutics’ investigational PD-1/VEGF bispecific antibody that represents a potential first-in-class therapy. AstraZeneca will purchase approximately 109,000 shares of convertible preferred stock, translating to a 12.0% stake in Summit's outstanding common stock, or 10.6% on a fully diluted basis. The transaction is expected to close within one week. The future conversion to common stock is subject to standard regulatory approvals. Beyond the finan
ADARx’s $446m IPO signals investor appetite for RNA therapeutics (opens the original)
Read excerpt
The San Diego-based biotech's upsized offering highlights growing confidence in siRNA innovation as the firm prepares for Nasdaq debut. Late-stage clinical biotechnology company ADARx Pharmaceuticals has announced the successful pricing of its upsized initial public offering (IPO). The firm raised approximately $446.3 million in gross proceeds – a clear signal that investors remain bullish on RNA-based innovation despite broader market uncertainties. The company priced 26,250,000 shares of commo
Rethinking biotech investment in a productivity-driven era (opens the original)
Read excerpt
M Ventures' Hakan Goker discusses navigating an era where speed, data depth, and commercial pragmatism define success. As pharmaceutical productivity challenges intensify and capital becomes more selective, investors and innovators alike are being forced to rethink their strategies. Artificial intelligence (AI) could revolutionize drug development, external innovation has become central to pharma R&D, and the bar for early-stage funding continues to rise. Ahead of BIO-Europe in Cologne, Germany,
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 10M sites
For SCM, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.